16 research outputs found
Nonlinear effects in resonant layers in solar and space plasmas
The present paper reviews recent advances in the theory of nonlinear driven
magnetohydrodynamic (MHD) waves in slow and Alfven resonant layers. Simple
estimations show that in the vicinity of resonant positions the amplitude of
variables can grow over the threshold where linear descriptions are valid.
Using the method of matched asymptotic expansions, governing equations of
dynamics inside the dissipative layer and jump conditions across the
dissipative layers are derived. These relations are essential when studying the
efficiency of resonant absorption. Nonlinearity in dissipative layers can
generate new effects, such as mean flows, which can have serious implications
on the stability and efficiency of the resonance
Excitation of standing kink oscillations in coronal loops
In this work we review the efforts that have been done to study the
excitation of the standing fast kink body mode in coronal loops. We mainly
focus on the time-dependent problem, which is appropriate to describe flare or
CME induced kink oscillations. The analytical and numerical studies in slab and
cylindrical loop geometries are reviewed. We discuss the results from very
simple one-dimensional models to more realistic (but still simple) loop
configurations. We emphasise how the results of the initial value problem
complement the eigenmode calculations. The possible damping mechanisms of the
kink oscillations are also discussed
Physics of Solar Prominences: II - Magnetic Structure and Dynamics
Observations and models of solar prominences are reviewed. We focus on
non-eruptive prominences, and describe recent progress in four areas of
prominence research: (1) magnetic structure deduced from observations and
models, (2) the dynamics of prominence plasmas (formation and flows), (3)
Magneto-hydrodynamic (MHD) waves in prominences and (4) the formation and
large-scale patterns of the filament channels in which prominences are located.
Finally, several outstanding issues in prominence research are discussed, along
with observations and models required to resolve them.Comment: 75 pages, 31 pictures, review pape
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial
Objective. Adalimumab, a fully human, antitumor necrosis factor monoclonal antibody, was evaluated for its safety and efficacy compared with placebo in the treatment of active psoriatic arthritis (PsA). Methods. Patients with moderately to severely active PsA and a history of inadequate response to nonsteroidal antiinflammatory drugs were randomized to receive 40 mg adalimumab or placebo subcutaneously every other week for 24 weeks. Study visits were at baseline, weeks 2 and 4, and every 4 weeks thereafter. The primary efficacy end points were the American College of Rheumatology 20% improvement (ACR20) response at week 12 and the change in the modified total Sharp score of structural damage at week 24. Secondary end points were measures of joint disease, disability, and quality of life in all patients, as well as the severity of skin disease in those patients with psoriasis involving at least 3% of body surface area. Results. At week 12, 58% of the adalimumab-treated patients (87 of 151) achieved an ACR20 response, compared with 14% of the placebo-treated patients (23 of 162) (P < 0.001). At week 24, similar ACR20 response rates were maintained and the mean change in the modified total Sharp score was -0.2 in patients receiving adalimumab and 1.0 in those receiving placebo (P < 0.001). Among the 69 adalimumab-treated patients evaluated with the Psoriasis Area and Severity Index (PASI), 59% achieved a 75% PASI improvement response at 24 weeks, compared with 1% of the 69 placebo-treated patients evaluated (P < 0.001). Disability and quality of life measures were also significantly improved with adalimumab treatment compared with placebo. Adalimumab was generally safe and well-tolerated. Conclusion. Adalimumab significantly improved joint and skin manifestations, inhibited structural changes on radiographs, lessened disability due to joint damage, and improved quality of life in patients with moderately to severely active PsA. © 2005, American College of Rheumatology.SCOPUS: ar.jinfo:eu-repo/semantics/publishe
Search for supersymmetry in events with photons, bottom quarks, and missing transverse momentum in proton-proton collisions at a centre-of-mass energy of 7 TeV with the ATLAS detector
Contains fulltext :
111247.pdf (preprint version ) (Open Access